Sandbox Reserved 1170: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 32: Line 32:


=== TAK-875 ===
=== TAK-875 ===
[[Image:Tak-875.png |300 px|right|thumb|Figure 4. Structure of TAK-875]] One example of an hGPR40 agonist is <scene name='72/721542/Tak875/2'>Tak-875</scene>. TAK-875 has shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.<ref name="Burant"/> This drug was studied in stage III clinical trials and was able to significantly reduce [[HbA1c]] and fasting plasma glucose levels in Japanese patients with type 2 diabetes that was not controlled by diet and exercise. However, clinical trials were stopped shortly after this study because TAK-875 was suspected of causing liver damage.<ref name="Kaku">PMID:25787200</ref>   
[[Image:Tak-875.png |300 px|right|thumb|Figure 4. Structure of TAK-875]] One example of an hGPR40 agonist is <scene name='72/721542/Tak875/2'>Tak-875</scene>. TAK-875 has shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.<ref name="Burant"/> This drug was studied in stage III clinical trials and was able to significantly reduce [http://www.diabetes.co.uk/what-is-hba1c.html HbA1c] and fasting plasma glucose levels in Japanese patients with type 2 diabetes that was not controlled by diet and exercise. However, clinical trials were stopped shortly after this study because TAK-875 was suspected of causing liver damage.<ref name="Kaku">PMID:25787200</ref>   




Retrieved from "https://proteopedia.org/Sandbox_Reserved_1170"